JAKARTA, Indonesia, Sept. 28, 2022 /PRNewswire/ PT Etana Biotechnologies Indonesia (Etana), an Indonesian biopharmaceutical company, has secured B round of financing led by Yunfeng Capitaland followed by HighLight Capital. This round of financing will be mainly used for further strengthening the company's pipeline & licensing for new products, teams as well as capacity expansions. Etana is leading the development of the Indonesian biopharmaceutical industry and progressing to be the ASEAN leader in biopharmaceutical commercialization. Currently, Etana focus on local biopharmaceutical production for mRNA platforms, proteins and Monoclonal antibodies. Nathan Tirtana, Founder of Etana stated "Etana, as an Indonesian biopharmaceutical start-up, always strive to provide high quality, affordable and innovative biopharmaceutical products to serve the patients in Indonesia and South-East Asian countries. We will use the support obtained from the investors to develop local biopha
Shanghai
China
Hong-kong
Shenzhen
Guangdong
Yunfeng
Sichuan
Beijing
Indonesia
Jakarta
Jakarta-raya
Indonesian